{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117219","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.446606+00:00","generated_at":"2026-06-21T23:42:33.456300+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vaccitech Q3 net income $8.2M; cash $200.1M; first patient dosed in VTP-300 Phase 2b","bullets":["Net income of $8.2M ($0.22 per share) vs $15.7M in Q2 2022; revenue fell to $6.2M from $17.1M as no milestones.","Cash and equivalents $200.1M as of Sep 30, 2022, down from $214.1M at Dec 31, 2021; cash runway into Q1 2025.","Dosed first patient in Phase 2b trial of VTP-300 for HBV; Phase 1b/2a data showed HBsAg reduction in CHB patients.","Promoted Gemma Brown to CFO effective Sep 20, 2022.","Expects to open Phase 1/2 trial for prostate cancer candidate VTP-850 in Q4 2022; IND submissions for SNAPvax programs in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117219","json":"https://secwatch.observer/filing/0001104659-22-117219.json","markdown":"https://secwatch.observer/filing/0001104659-22-117219.md","text":"https://secwatch.observer/filing/0001104659-22-117219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/0001104659-22-117219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/tm2230034d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:42:33.456300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4383fd87886fcac88abfe8ad4d20623fec57fbac","claim":"Barinthus Biotherapeutics plc. reported third quarter ended September 30, 2022 results: revenue $6.2 million, net income $8.2 million, EPS $0.22 both per fully diluted share and per basic share.","evidence_excerpt":"Revenues comprised primarily of the Company’s share of milestone and royalty payments received by OUI from AstraZeneca related to commercial sales of Vaxzevria ® . Revenues were $6.2 million in the third quarter of 2022 compared to $17.1 million in the second quarter of 2022, with the reduction attributable to no milestones being achieved in the third quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/0001104659-22-117219-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$6.2 million"},{"label":"Net income","value":"$8.2 million"},{"label":"EPS","value":"$0.22 both per fully diluted share and per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}